Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 551 participants.
Also called NCT06353347
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 551 participants
- Registry
-
NCT06353347
-
- Other papers using this trial's data
- HTD1801 in Combination with Metformin for Type 2 Diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06353347. Randomized; double masking; primary purpose treatment. Start 2023-11-13 (actual); primary completion 2024-12-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
- Acronym
- SYMPHONY-2
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- HTD1801
- Intervention (Drug)
- Placebo
- Lead sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.
Record details
- Record id
cardio:ct-nct06353347- Content hash
6efe4ba0f9645a0ee8b1ab1a06820f0cbe68dd464d501269f7821d3b56cceeab